**Clinical Trial Inclusion Criteria**

1. Patients with advanced stage ovarian cancer, stages III or IV, who have been treated to complete remission with standard therapies including primary debulking surgery.

2. A CA-125 level within normal limits for the testing laboratory must be documented 90 days prior to enrollment when the assessment of CA-125 is applicable.

3. Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy, prior to enrollment.

4. Patients must be at least 28 days post systemic steroids prior to enrollment.

5. Patients must have ECOG Performance Status Score of ≤ 2 (Appendix A).

6. Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment.

7. Estimated life expectancy of more than 6 months.

8. Adequate laboratory values within 30 days of enrollment to study defined as follows:
   
   a. WBC ≥ 3000/mm$^3$
   b. Hgb ≥ 10 mg/dl
   c. Hct ≥ 28%
   d. Serum creatinine ≤ 2.0 mg/dl or creatinine clearance > 60 ml/min
   e. Total bilirubin ≤ 2.5 mg/dl
   f. AST/SGOT ≤ 3 times ULN
   g. Blood glucose < 1.5 ULN

9. Patients must be at least 18 years of age.

**Clinical Trial Exclusion Criteria**

1. Patients with any of the following cardiac conditions:
   
   a. Symptomatic restrictive cardiomyopathy
   b. Unstable angina within 4 months prior to enrollment
   c. New York Heart Association functional class III-IV heart failure on active treatment
   d. Symptomatic pericardial effusion

2. Uncontrolled diabetes

3. Patients with any contraindication to receiving rhuGM-CSF based products

4. Ovarian cancer of a low malignant potential phenotype or clear cell histology

5. Patients with any clinically significant autoimmune disease uncontrolled with treatment

6. Patients who are currently receiving an anti-IGF-IR monoclonal antibody as part of their treatment regimen

7. Patients who are simultaneously enrolled in any other treatment study

8. All subjects able to bear children

For additional details on this clinical trial, please see http://clinicaltrials.gov/ct2/show/NCT01322802?term=disis+IGFBP2&rank=1"